Skip to main content
. 2023 Jan 4;13:972878. doi: 10.3389/fphar.2022.972878

FIGURE 5.

FIGURE 5

Model prediction. (A) Actual maximal efficacy (AEmax) of dapagliflozin on HbA1c; (B) after it reached the AEmax, the dapagliflozin therapeutic effect on HbA1c continuing the treatment for 0.5 years (26 weeks), at week 35; and (C) after it reached the AEmax, the dapagliflozin therapeutic effect on HbA1c continuing the treatment for 1 year (52 weeks) at week 61.